Abstract
To investigate the metabolic cost of catecholamine use in heart failure, we administered intravenous dobutamine or norepinephrine to dogs with moderate and severe LV dysfunction until LV contractile function was restored to normal levels. Both drugs were associated with significant increases in myocardial O(2) consumption, increased coronary blood flow requirements and decreased myocardial mechanical efficiency. These mechanisms may contribute to the deleterious effects of catecholamines in heart failure.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenergic alpha-Agonists / administration & dosage
-
Adrenergic beta-Agonists / administration & dosage
-
Animals
-
Blood Flow Velocity / drug effects
-
Blood Pressure / drug effects
-
Cardiomyopathy, Dilated / drug therapy*
-
Cardiomyopathy, Dilated / metabolism
-
Cardiomyopathy, Dilated / physiopathology*
-
Catecholamines / administration & dosage
-
Catecholamines / pharmacology*
-
Coronary Circulation / drug effects*
-
Disease Models, Animal
-
Dobutamine / administration & dosage
-
Dogs
-
Dose-Response Relationship, Drug
-
Female
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology*
-
Heart Rate / drug effects
-
Heart Ventricles / drug effects
-
Heart Ventricles / physiopathology
-
Male
-
Models, Cardiovascular
-
Myocardial Contraction / drug effects*
-
Norepinephrine / administration & dosage
-
Oxygen Consumption / drug effects*
-
Severity of Illness Index
-
Stroke Volume / drug effects
-
Vasodilation / drug effects
Substances
-
Adrenergic alpha-Agonists
-
Adrenergic beta-Agonists
-
Catecholamines
-
Dobutamine
-
Norepinephrine